- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Article
Derms protest planned FDA ban
Schaumburg, Ill. - The American Academy of Dermatology (AAD) will object to a proposed federal ban of over-the-counter sales of hydroquinone.
Schaumburg, Ill. - The American Academy of Dermatology (AAD) will object to a proposed federal ban of over-the-counter sales of hydroquinone.
The Food and Drug Administration (FDA) has declared that products containing the bleaching agent pose risks of cancer and skin discoloration, and has proposed a ban on nonprescription sales.
If the agent is banned, all existing cosmetic products containing hydroquinone would need to submit a new drug application for the FDA's review, according to news reports.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
